Krystal Biotech's Total Assets for the quarter that ended in Mar. 2024 was $853.30 Mil.
During the past 12 months, Krystal Biotech's average Total Assets Growth Rate was 73.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 93.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 134.70% per year.
During the past 8 years, Krystal Biotech's highest 3-Year average Total Assets Growth Rate was 323.00%. The lowest was 93.40%. And the median was 250.90%.
The historical data trend for Krystal Biotech's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Krystal Biotech's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (NAS:KRYS) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Krystal Biotech's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Krystal Biotech Total Assets Related Terms
Thank you for viewing the detailed overview of Krystal Biotech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Krystal Biotech (Krystal Biotech) Business Description
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRYS has been successfully added to your 